ABIVAX press release
Michael Ferguson is appointed Chief Commercial Officer of Abivax.
Michael Ferguson has recognized experience in the biopharmaceutical industry and held senior positions for the commercialization and marketing of drugs in the field of gastroenterology, more particularly in the field of inflammatory bowel disease (IBD). ).
As Chief Commercial Officer, Michael Ferguson will lead the market development of obefazimod in IBD, beginning with ulcerative colitis.